Q4 2023 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2024-02-14 · accession 0001937964-24-000001
$343.7M
Reported value
31
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670100205 | NVO | NOVO-NORDISK A S | $74.6M | 21.7% | 721,507 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $54.0M | 15.7% | 92,593 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $35.9M | 10.4% | 329,200 | Common | SOLE |
| 23282W905 | — | CYTOKINETICS INC | $33.8M | 9.83% | 404,900 | CALL | SOLE |
| 23282W955 | — | CYTOKINETICS INC | $33.4M | 9.73% | 400,500 | PUT | SOLE |
| 532457958 | — | ELI LILLY & CO | $23.3M | 6.78% | 40,000 | PUT | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $14.1M | 4.09% | 90,821 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $13.0M | 3.79% | 34,238 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $12.8M | 3.74% | 190,752 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $7.1M | 2.08% | 383,580 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $7.0M | 2.03% | 87,848 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $5.9M | 1.72% | 45,000 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $3.0M | 0.87% | 41,600 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $2.8M | 0.81% | 28,885 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $2.7M | 0.78% | 32,113 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $2.6M | 0.76% | 130,790 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $2.6M | 0.75% | 112,340 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $2.4M | 0.70% | 38,555 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $2.3M | 0.68% | 74,936 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $2.0M | 0.57% | 440,000 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $1.8M | 0.53% | 100,000 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $1.6M | 0.47% | 6,905 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $1.2M | 0.34% | 50,000 | Common | SOLE |
| 941848103 | WAT | WATERS CORP | $936,659 | 0.27% | 2,845 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $901,456 | 0.26% | 21,397 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $488,004 | 0.14% | 19,638 | Common | SOLE |
| 86366E956 | — | STRUCTURE THERAPEUTICS INC | $407,600 | 0.12% | 10,000 | PUT | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $369,563 | 0.11% | 25,452 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $290,045 | 0.08% | 10,381 | Common | SOLE |
| 39868T105 | 2JQ | GRITSTONE BIO INC | $194,147 | 0.06% | 95,170 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $142,004 | 0.04% | 10,253 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.